Robert Allison Franklin , MD

Bachelor of Arts: University of Georgia Atlanta, GA, 2008 (Philosophy, English Literature)

MD: University of Tennessee Health Science Center College of Medicine Memphis, TN, 2015 (Medicine)

Residency: University of Cincinnati Medical Center Cincinnati, Ohio, 2018 (Internal Medicine)

American Board of Internal Medicine (Certification Date: 08-24-2018 )

American Board of Internal Medicine (Hematology) (Certification Date: 11-30-2022 )

American Board of Internal Medicine (Medical Oncology) (Certification Date: 11-29-2022 )

Lung Cancer

Thoracic Cancer

Medical Oncology

Oncology

Bladder Cancer

Kidney Cancer

Penile Cancer

Prostate Cancer

Testicular Cancer

Internal Medicine

Hematology

Medical Oncology

Grant: #D9723C00001 Investigators:Franklin, Robert 04-08-2024 -04-08-2027 AstraZeneca Pharmaceuticals LP A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration Role:PI 0.00 Hold Level:Industry

Investigators:Franklin, Robert 04-29-2024 -05-29-2024 Myovant Sciences Relugolix Versus Leuprolide in Patients with PRostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV) Role:PI 0.00 Hold Level:Industry

Investigators:Franklin, Robert 11-15-2024 -11-15-2027 ICON Clinical Research, LLC A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma Role:PI 760375.95 Hold Level:Industry

Academic - University of Cincinnati Medical Center
234 Goodman St
Cincinnati  Ohio, 45219
Phone: 513-585-8222
franklro@ucmail.uc.edu